NEUROPATHIC OCULAR PAIN MARKET ANALYSIS

Regional Analysis

Global Neuropathic Ocular Pain Market- Regional Analysis

Among all regions, North America is expected to dominate the global market over the forecast period. This is attributed to North America holding a 34.8% market share and an increase in acquisition by the key market players in this region. For instance, in August 2022, Alcon Laboratories, a U.S.-based manufacturer of eye care products, announced that it had acquired Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye, to enhance the company's Ophthalmic Pharmaceutical Portfolio.

The Europe region is expected to be second dominating region over the forecast period, due to increase in the product launches in Europe. For instance, in January 2022, Alcon Laboratories, a U.S.-based manufacturer of eye care products, announced that it had launched Systane, a product to treat dry eyes and related pain, in Europe.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC Countries, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa